A phase II study of combined chemoradiotherapy for limited disease-small-cell lung cancer

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 23, Issue 2, 2000, Pages 197-202

  Ishihara, Shinichi ^a,b   Tsuchiya, Satoshi ^a   Minato, Koichi ^b   Watanabe, Satoru ^a   Sunaga, Noriaki ^a   Sato, Koji ^a   Kobayashi, Go ^a   Hoshino, Hideki ^b   Naruse, Ichirou ^b   Makimoto, Takeyuki ^b   Nomoto, Taisuke ^b   Takei, Yoshikazu ^b   Fueki, Naoto ^b   Takise, Atsushi ^b   Saito, Ryusei ^a   Mori, Masatomo ^b  

^a Shibukawa Medical Center   (Japan)

^b GUNMA UNIVERSITY   (Japan)

Author keywords

Combined chemoradiotherapy; Limited disease small cell lung cancer; Long term survivor

Indexed keywords

CISPLATIN; DOXORUBICIN; ETOPOSIDE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; ESOPHAGITIS; FEMALE; HUMAN; LEUKOPENIA; LUNG SMALL CELL CANCER; MALE; PHASE 2 CLINICAL TRIAL; PNEUMONIA; RADIATION DOSE FRACTIONATION; THROMBOCYTOPENIA; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SMALL CELL; CISPLATIN; COMBINED MODALITY THERAPY; DOXORUBICIN; ESOPHAGITIS; ETOPOSIDE; FEMALE; HUMANS; LEUKOPENIA; LUNG NEOPLASMS; MALE; MIDDLE AGED; SURVIVAL ANALYSIS; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0033639058     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-200004000-00018     Document Type: Article

References (30)

1. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: A phase III trial of the South-eastern Cancer Study Group
2. Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer
3. Cis-dichlorodiammineplatinum(II): Combination chemotherapy and cross-resistance studies with tumors of mice
4. Combined modality therapy for small call lung cancer
5. A meta-analysis of thoracic radiotherapy for small-cell lung cancer
6. Effect of thoracic radiotherapy on mortality in limited small cell lung cancer. A meta-analysis of 13 randomized trials among 2140 patients
7. Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis
8. Concurrent cisplatin-etoposide chemotherapy plus thoracic radiotherapy for limited-stage small cell lung cancer
9. Observations after 5 year follow-up of intergroup trial 0096: 4 Cycles of cisplatin etoposide and concurrent 45 Gy thoracic radiotherapy given in daily or twice-daily fractions followed by 25 Gy PCI. Survival differences and patterns of failure
10. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small cell lung cancer: Preliminary results of the Japan Clinical Oncology Group
11. A preliminary report: Concurrent twice-dally radiotherapy plus platinum-etoposide chemotherapy for limited small cell lung cancer
12. Concurrent chemotherapy/radiotherapy for limited small-cell lung carcinoma: A South-west Oncology Group Study
13. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples
14. Reporting results of cancer treatment
15. Etoposide (VP-16) and cisplatin: An effective treatment for relapse in small-cell lung cancer
16. VP-16 and cisplatin as first-line therapy for small-cell lung cancer
17. Cisplatin and etoposide combination chemotherapy for refractory small cell carcinoma of the lung
18. Cis-dichlorodiammineplatinum(lI) and VP-16-213: An active induction regimen for small cell carcinoma of the lung
19. Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer
20. Chemotherapy with or without radiation therapy in limited small cell carcinoma of the lung
21. Initial versus delayed accelerated hyperfractionated radiation therapy and concurrent chemotherapy in limited small-cell lung cancer: A randomized study
22. Importance of radiation dose in achieving improved locoregional tumor control in limited small-cell lung carcinoma: An update
23. Infusion cisplatin chemotherapy and hyperfractionated thoracic radiotherapy for small-cell lung cancer
24. Treatment of limited-disease small cell lung cancer
25. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission
26. Prophylactic cranial irradiation overview in patients with small cell lung cancer in complete remission
27. Intensive combination chemotherapy, concurrent chest irradiation, and warfarin for the treatment of limited-disease small-cell lung cancer: A Cancer and Leukemia Group B pilot study
28. Radiation pneumonitis following combined modality therapy for lung cancer: Analysis of prognostic factors
29. The use of drugs in combination for the treatment of cancer